2993-07-9

Basic information

• Product Name: 3,4,5,6-tetrafluorobenzene-1,2-diaMine
• Synonyms: 3,4,5,6-tetrafluorobenzene-1,2-diaMine;Tetrafluorobenzene-1,2-diamine 85%;Tetrafluorophenylene-1,2-diamine, 1,2-Diaminotetrafluorobenzene, 3,4,5,6-Tetrafluorobenzene-1,2-diamine
• CAS NO: 2993-07-9
• Molecular Formula: C₆H₄F₄N₂
• Molecular Weight: 180.1029728
• Mol File: 2993-07-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 130～132℃
• Boiling Point: 246.4±35.0 °C(Predicted)
• Appearance: /
• Density: 1.624±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.10±0.10(Predicted)
• CAS DataBase Reference: 3,4,5,6-tetrafluorobenzene-1,2-diaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4,5,6-tetrafluorobenzene-1,2-diaMine(2993-07-9)
• EPA Substance Registry System: 3,4,5,6-tetrafluorobenzene-1,2-diaMine(2993-07-9)

Safety Data

• Hazardous Substances Data: 2993-07-9(Hazardous Substances Data)

Usage

Uses

1,2-Diamino-3,4,5,6-tetrafluorobenzene (CAS# 2993-07-9) can be prepared for halogenated compounds to induce Hep2 cell apoptosis.

Upstream product

• 1801-15-6 2-(2,3,4,5,6-pentafluoro-anilino)-ethanol 
• 30807-79-5 C₆HBCl₂F₅N 
• 2247-97-4 3-N₂H₃-C₆F₄NH₂ 
• 771-60-8 2,3,4,5,6-pentafluoroaniline 
• 123394-96-7 1-pentafluorophenyl-3-trimethylsilyl-1,3-diaza-2-thiaallene 
• 880-78-4 pentafluoronitrobenzen 
• 344-07-0 1-chloro-2,3,4,5,6-pentafluorobenzene 
• 75207-77-1 4.5.6.7-tetrafluorobenzo-2.1.3-thiadiazole 
• 6157-98-8 2,3,4,5-tetrafluoro-6-nitroaniline 
• 7732-18-5 water 
• 16582-88-0 N-(2,3,4,5-tetrafluorophenyl)acetamide 

Downstream Products

• 26888-72-2 4,5,6,7-tetrafluorobenzotriazole 
• 4920-46-1 4,5,6,7-tetrafluorobenzimidazole 
• 4920-47-2 4,5,6,7-tetrafluoro-N-methylbenzimidazole 
• 1331779-66-8 6,7,8,9-tetrafluoro-11H-benzo[4,5]imidazo[2,1-a]isoindol-11-one 
• 1258949-68-6 N,N'-bis-pentafluorophenyl-3,4,5,6-tetrafluorophenylene-1,2-diamine 
• 554-68-7 triethylamine hydrochloride 
• 1240404-70-9 N,N'-disulfinyl-3,4,5,6-tetrafluoro-1,2-diaminobenzene 
• 81430-68-4 1-ethyl-2-methyl-3,3,3-trifluoropropyl-4,5,6,7-tetrafluorobenzimidazolium p-toluenesulfonate 
• 81430-66-2 1,3-diethyl-2-methyl-4,5,6,7-tetrafluorobenzimidazolium p-toluenesulfonate 
• 81430-75-3 2-methyl-4,5,6,7-tetrafluorobenzimidazole 
• 2355-43-3 4,5,6,7-Tetrafluor-2-trifluormethyl-benzimidazol 
• 39063-17-7 N,N-(perfluoro-1,2-phenylene)bis(2,2,2-trifluoroethanamide) 
• 26888-63-1 5,6,7,8-tetrafluoro-2,3-diphenylquinoxaline 

Relevant articles and documents

2-(4,5,6,7-Tetrafluorobenzimidazol-2-yl)-4,4,5,5-tetramethyl-4,5-dihydro-1- H-imidazole-3-oxide-1-oxyl, a hydrogen-bonded organic quasi-1D ferromagnet

The title radical (F4BImNN) is a stable nitronylnitroxide that forms hydrogen-bonded NH?ON chains in the solid state. The chains assemble the F4BImNN molecules to form stacked contacts between the radical groups, in a geometry that is expected to exhibit

Catalytic and noncatalytic ammonolysis of chloropentafluorobenzene

Ammonolysis of chloropentafluorobenzene both in the presence and in the absence of copper(I) salt results mainly in replacement of the para-and ortho-fluorine atoms with respect to chlorine rather than replacement of the chlorine atom. Ammonolysis of 4-chloro-2,3,5,6-tetrafluoroaniline and 2-chloro-3,4,5,6-tetrafluoroaniline in the absence of copper(I) salt yields exclusively the corresponding fluorine substitution products, whereas in the presence of copper(I) salt the chlorine atom is replaced. Successive ammonolysis of chloropentafluorobenzene in the presence of copper catalyst along these two paths was put into the basis of a new method for preparation of 2,3,5,6-tetrafluoro-1,4-phenylenediamine. * This study was financially supported by the Russian Foundation for Basic Research (project no. 99-03-33111), by the Ministry of Science and Technology of the Russian Federation (project no 9.3.01), and by the Ministry of Education of the Russian Federation (project no. 015.05.01.13).

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.